Background: Polynucleotides (PN) are innovative polymers that improve skin hydration and elasticity, serving as alternatives to traditional dermal fillers. Medical devices based on PN High Purification Technology (PN HPT) represent a new generation of injectable products designed to restore hydration, elasticity, and overall tissue quality. PN HPT is known for its clinical versatility and excellent tolerability.
Aims: To assess the real-world performance and safety of Plinest (40 mg/2 mL of PN HPT in a 2 mL pre-filled syringe), a CE-marked class III medical device for skin rejuvenation of the face, neck, and décolleté.
Methods: This observational clinical data collection involved 66 adult patients, each of whom could receive treatment in up to three areas (face, neck, décolleté). Patients underwent three sessions of intradermal PN HPT injections. A total of 106 questionnaires were collected: 47 for the face, 33 for the neck, and 26 for the décolleté. Performance was evaluated using the Global Clinical Improvement Scale (GCI-S) and Global Aesthetic Improvement Scale (GAIS). Safety was monitored through spontaneous adverse event (AE) reporting.
Results: Clinician-reported outcomes showed visible improvement in 100% of facial treatments, with 53.5% rated as "marked" or "excellent." In the neck and décolleté areas, moderate to significant improvements were observed in over 93% and 88% of cases, respectively. Patient satisfaction ranged from 97% to 100%. No serious AEs occurred.
Conclusions: PN HPT demonstrated a favorable tolerability and performance profile in real-life aesthetic practice, supporting its role in improving skin quality and reducing signs of aging.
Keywords: PN HPT; Polynucleotides High Purification Technology; polynucleotides; skin quality; skin rejuvenation.
© 2026 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.